For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Landscape Analysis of Alzheimer's Disease-Specific Caregiver Outcome Assessments
Economic Burden of SLE in Nordic Countries - a Systematic Literature Review (SLR)
Is our evidence enough? – A review of G-BA´s ongoing evidentiary requirements in the oncology space
Are all unmet needs worth the same when financing health? A review of HTA disease prioritization in Europe
Efficacy of Anti-Alzheimer’S (AD) Drugs in Cognitive Improvement: A Network Meta-Analysis (NMA) of Randomized Controlled Trials (RCTS)
Top 5% Finalist | Bridging the gap between national and EUnetHTA21 HTA methods. Are marketing authorization holders ready for joint clinical assessments?
Are we leaving no one behind? – Health technology assessment as a pathway to social justice
How Will Recent Pricing Regulations Impact the Global Pricing Landscape?
Are Digital Health Therapeutics Reshaping the HTA Framework for Health Technologies?
Impact of TCET legislation on break-through designated devices
A conceptual modeling framework for manufacturers to navigate the Inflation Reduction Act and to negotiate a “fair maximum price”
HTA guidance updates and usage of Real-World Evidence (RWE) in reimbursement decisions - A 2023 perspective
Is the Paradigm Shifting? The REvalMED Pilot Program and Subsequent Integration of Economic Evaluations to Influence Pricing and Reimbursement Discussions in Spain
Is There Equity of Access to Highly Specialised Treatments between England and Northern Ireland?
Overview of COA Measures in SLE Clinical Trials and Label Claims
Non-Communicable Diseases Prevention in India: A Review of Suitable Instruments for Surveillance and a General Overview of Cultural, Behavioral Practices and Risk Factors for the Adult Population.
A Systematic Review of the Use of Registry-Based Randomized Controlled Trials (R-RCTs) for Regulatory Approval and Access
Implement a Direct-to-Patient Application to Recruit Diverse Patients and Collect Real-World Data
Cost-effectiveness analysis of nivolumab plus relatlimab versus nivolumab monotherapy for patients with advanced melanoma in The Netherlands
Multinational Real-World Data in Transplant Patients with Refractory/Resistant Cytomegalovirus Infection Enhance Cost-Effectiveness Modelling Outcomes
Real-World Evidence in Post-Authorization Studies: Review of European Databases in the ENCePP EU Pas Register® Between 2010 – 2023
Tip for Excel(lent) modelling - or R there better alternatives?
Formulating Bayesian Poly-Hazard Models for Informed and Clinically Interpretable Lifetime Survival Extrapolations in Advanced Non-Small Cell Lung Cancer (aNSCLC)
It's Alive! Feasibility and Benefits of Living Cost-Effectiveness Modeling Following a Living SLR
Radiographic progression free survival as surrogate endpoint for overall survival among men with Metastatic Castration-Resistant Prostate Cancer
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States
Looking sharp! Applying cutting-edge Shapley Additive explanation (SHAP) approaches to cost-effectiveness modelling in contrast to one-way sensitivity analysis
Geographic search filters for embase.com interface: an analysis utilizing multiple case studies
Inferring the proportion of durable responders to targeted oncology therapies in combination regimens using Bayesian parametric mixture survival models
Extending Bayesian Evidence Synthesis to Include Historical Trial Data for Improved Survival Extrapolations from Early Data Cuts in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Long COVID Symptom Diary: Development of a PRO Instrument to Support Drug Development and Regulatory Submissions in Europe
The Use of Copilot, a Generative Artificial Intelligence Tool, as VBA Programming Assistant in Excel-Based Health Economic Models
Do health technology assessment (HTA) bodies recommend the conduct and submission of artificial intelligence-based literature reviews (AILRs)?
Advancing Causal Inference With Machine Learning and Real-World Data: An Application of Targeted Machine Learning and Super Learners on Hospital-Acquired Pressure Injuries From MIMIC IV
Causal Machine Learning for Assessing Pneumococcal Vaccine Effectiveness: Innovations in Real-World Data Analysis and Confounding Pathway Adjustment
A Review of Migraine-Related Pros in FDA Labelling Claims (2018-2023)
Increasing patient access in Scandinavia through Outcome Based Agreements: Can the Spanish model be replicated?
Survey Research Using PRO Data in Clinical Practice: Lessons Learnt from the Nordic Countries
Integration of Clinical Outcome Assessments (COA) in Drug Approval Process to Foster Patient-Centric Clinical Trials: A Review of 3 Regulatory Guidelines for Drug Development in the APAC
Comparing UK value sets and mapping functions for EQ-5D
A Review of Patient-Reported Outcomes and External Control Arms in Regulatory Submissions of Novel Oncology Drugs
Incorporating Patient Perspectives in HTA Assessments for Rare Diseases: Insights From Multiple HTA Assessments